Individualizing duration of antibiotic therapy in community-acquired pneumonia. (August 2017)
- Record Type:
- Journal Article
- Title:
- Individualizing duration of antibiotic therapy in community-acquired pneumonia. (August 2017)
- Main Title:
- Individualizing duration of antibiotic therapy in community-acquired pneumonia
- Authors:
- Aliberti, Stefano
Ramirez, Julio
Giuliani, Fabio
Wiemken, Timothy
Sotgiu, Giovanni
Tedeschi, Sara
Carugati, Manuela
Valenti, Vincenzo
Marchioni, Marco
Camera, Marco
Piro, Roberto
Del Forno, Manuela
Milani, Giuseppe
Faverio, Paola
Richeldi, Luca
Deotto, Martina
Villani, Massimiliano
Voza, Antonio
Tobaldini, Eleonora
Bernardi, Mauro
Bellone, Andrea
Bassetti, Matteo
Blasi, Francesco - Abstract:
- Abstract: International experts suggest tailoring antibiotic duration in community-acquired pneumonia (CAP) according to patients' characteristics. We aimed to assess the effectiveness of an individualized approach to antibiotic duration based on time in which CAP patients reach clinical stability during hospitalization. In a multicenter, non-inferiority, randomized, controlled trial hospitalized adult patients with CAP reaching clinical stability within 5 days after hospitalization were randomized to a standard vs . individualized antibiotic duration. In the Individualized group, antibiotics were discontinued 48 h after the patient reached clinical stability, with at least five days of total antibiotic treatment. Early failure within 30 days was the primary composite outcome. 135 patients were randomized to the Standard group and 125 to the Individualized group. The trial was interrupted by the safety committee because of an apparent inferiority of the Individualized group over the Standard treatment: 14 (11.2%) patients in the Individualized group experienced early failure vs . 10 (7.4%) patients in the Standard group, p = 0.200, at the intention-to-treat analysis. 30-day mortality rate was four-time higher in the Individualized group than the Standard group. Shortening antibiotic duration according to patients' characteristics still remains an open question.
- Is Part Of:
- Pulmonary pharmacology & therapeutics. Volume 45(2017:Aug.)
- Journal:
- Pulmonary pharmacology & therapeutics
- Issue:
- Volume 45(2017:Aug.)
- Issue Display:
- Volume 45 (2017)
- Year:
- 2017
- Volume:
- 45
- Issue Sort Value:
- 2017-0045-0000-0000
- Page Start:
- 191
- Page End:
- 201
- Publication Date:
- 2017-08
- Subjects:
- Respiratory organs -- Diseases -- Chemotherapy -- Periodicals
615.7205 - Journal URLs:
- http://www.sciencedirect.com/science/journal/10945539 ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/pulmonary-pharmacology-and-therapeutics/ ↗ - DOI:
- 10.1016/j.pupt.2017.06.008 ↗
- Languages:
- English
- ISSNs:
- 1094-5539
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7156.978500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 2922.xml